ADMGCN:用于阿尔茨海默病诊断的图形卷积网络,使用元学习范式
Xiaowen Sun1,2, Jiahao Li2, Guiying Yan3,4
1College of Medical Information and Engineering, Ningxia Medical University, Yinchuan 750004, China.
Bioinformatics (Oxford, England)
|October 28, 2025
概括
一个新的元学习图形卷积网络 (ADMGCN) 通过解决数据局限性来改善早期阿尔茨海默病诊断. 这种方法提高了神经退行性疾病的诊断准确性和效率.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 计算神经科学是一种神经科学.
背景情况:
- 阿尔茨海默病 (AD) 诊断面临深度学习的挑战,包括大数据集需求和不平衡的数据.
- 图形卷积网络 (GCNs) 通过整合结构和多模式数据,显示了AD诊断的前景.
- 现有的深度学习方法在阿尔茨海默病研究中扎着数据限制和标签不平衡.
研究的目的:
- 提出一个基于元学习的图形卷积网络 (ADMGCN) 以提高早期阿尔茨海默病诊断.
- 通过整合加权和缩小维度来提高GCN的灵活性,性能和培训效率.
- 利用元学习来创建标签平衡的任务,最大限度地利用数据并减轻不平衡问题.
主要方法:
- 开发了ADMGCN,一个使用元学习范式的图形卷积网络.
- 在ADMGCN框架内实施加权和缩小维度的技术.
- 采用受雇主体抽样,生成多个标签平衡的任务,用于元学习.
主要成果:
- 在早期ADD诊断的多分类中,ADMGCN达到73.7%的最大准确率.
- 该模型在二进制分类任务中表现出强的表现,准确率为92.8%,88.0%和79.6%.
- 验证是在阿尔茨海默病神经成像倡议数据集上进行的.
结论:
- 拟议的ADMGCN方法为早期阿尔茨海默病诊断提供了一种有效的方法.
- ADMGCN为提高诊断准确性和效率提供了宝贵的支持.
- 超级学习框架有助于快速适应和独立测试用于AD研究的GCN.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.5K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.3K
相关概念视频
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
